Compare Medpace Holdings Inc (MEDP) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Mesoblast Limited — how do they compare? Medpace Holdings Inc trades at $527.48 (market cap $15.35B), while Mesoblast Limited trades at $16.6 (market cap $2.18B). The key difference: Medpace Holdings Inc is far larger — about 7× Mesoblast Limited's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MEDP | MESO | |
|---|---|---|
Market Cap | $15.35B | $2.18B |
Sector | Technology | Technology |
52-Week High | $620.59 | $20.96 |
52-Week Low | $308.88 | $12.88 |
Enterprise Value | $14.82B | $2.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $534.31, down 0.64% today, with a bullish technical signal from moving averages. The company shows strong profitability with 17.19% net margin and 77.25% ROE, though valuation ratios appear elevated with P/E of 33.83. Recent earnings have consistently beaten expectations, and 2026 projections indicate continued revenue growth to $2.7B. However, the stock faces headwinds from a class action lawsuit and mixed analyst sentiment with only 21% buy ratings.
MEDP presents a mixed outlook with strong fundamental performance offset by valuation concerns and legal risks. The stock trades above the consensus price target of $497, suggesting limited near-term upside. Earnings consistency and CRO industry demand provide support, but investors should weigh the high valuation against litigation overhang and cautious Wall Street positioning.
MESO trades at $16.57, down 4.33% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong revenue growth with Ryoncil generating $115 million annually, though it remains unprofitable with a -144% net income margin. Recent milestones include Phase 3 trial completions and FDA BLA progress for heart failure treatment.
Investment outlook balances promising commercial progress against significant financial risks. The stock offers growth potential from FDA approvals and expanding revenues, but high cash burn and negative earnings require careful risk management. Analyst consensus leans bullish with 45% buy ratings, though profitability challenges persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
